MX2018000216A - Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos. - Google Patents
Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos.Info
- Publication number
- MX2018000216A MX2018000216A MX2018000216A MX2018000216A MX2018000216A MX 2018000216 A MX2018000216 A MX 2018000216A MX 2018000216 A MX2018000216 A MX 2018000216A MX 2018000216 A MX2018000216 A MX 2018000216A MX 2018000216 A MX2018000216 A MX 2018000216A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- solid tumors
- treatment
- hematological cancers
- cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente métodos para tratar, prevenir y/o controlar cánceres hematológicos y tumores sólidos mediante el uso de una terapia de combinación de 3-(5-amino-2-4-oxo-4H-quinazo lin-3-il)-piperidina-2,6-diona e inhibidores de puntos de control.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562188404P | 2015-07-02 | 2015-07-02 | |
US201562245916P | 2015-10-23 | 2015-10-23 | |
US201662308055P | 2016-03-14 | 2016-03-14 | |
US201662340972P | 2016-05-24 | 2016-05-24 | |
PCT/US2016/040718 WO2017004532A1 (en) | 2015-07-02 | 2016-07-01 | Combination therapy for treatment of hematological cancers and solid tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018000216A true MX2018000216A (es) | 2018-05-22 |
Family
ID=56418624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000216A MX2018000216A (es) | 2015-07-02 | 2016-07-01 | Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US10973822B2 (es) |
EP (1) | EP3316888A1 (es) |
JP (2) | JP6727237B2 (es) |
KR (1) | KR20180023968A (es) |
AU (1) | AU2016288246A1 (es) |
BR (1) | BR112017028530A2 (es) |
CA (1) | CA2991164A1 (es) |
EA (1) | EA201890199A1 (es) |
MX (1) | MX2018000216A (es) |
WO (1) | WO2017004532A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180086195A (ko) * | 2015-10-21 | 2018-07-30 | 테크리슨 리미티드 | 면역 매개 암 치료를 위한 조성물 및 방법 |
CA3006758A1 (en) | 2015-12-02 | 2017-06-08 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
AU2018284101A1 (en) * | 2017-06-12 | 2019-12-19 | Les Laboratories Servier | Methods of treating brain tumors using combination therapy |
TWI821189B (zh) | 2017-06-12 | 2023-11-11 | 法商施維雅藥廠 | 使用組合療法治療腦腫瘤之方法 |
MX2020003395A (es) * | 2017-10-13 | 2020-08-03 | Merck Sharp & Dohme | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. |
WO2019094931A1 (en) * | 2017-11-10 | 2019-05-16 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
JP2021532140A (ja) * | 2018-07-30 | 2021-11-25 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与 |
EP3974455A4 (en) * | 2019-05-21 | 2023-06-14 | Kuraray Noritake Dental Inc. | RESIN COMPOSITION FOR OPTICAL THREE-DIMENSIONAL MODELING |
US20220298580A1 (en) * | 2019-08-30 | 2022-09-22 | Dana-Farber Cancer Institute, Inc. | Immune signatures predictive of response to pd-1 blockade in richter's transformation |
US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
WO2021092190A1 (en) * | 2019-11-05 | 2021-05-14 | Health Research, Inc. | Combination therapy for cancer |
WO2021118353A1 (en) * | 2019-12-11 | 2021-06-17 | Erasmus University Medical Center Rotterdam | Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias |
US20220117929A1 (en) * | 2020-10-21 | 2022-04-21 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating high-grade serous carcinoma |
WO2023077090A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
CN115137731B (zh) * | 2022-05-19 | 2023-11-21 | 上海交通大学医学院附属新华医院 | Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
CN104211684A (zh) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体 |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP2683384B1 (en) | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
CN104755472A (zh) | 2012-09-04 | 2015-07-01 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法 |
BR112015005243A2 (pt) * | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
MX363652B (es) | 2013-05-01 | 2019-03-28 | Celgene Corp | Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona. |
JP2016521280A (ja) * | 2013-05-03 | 2016-07-21 | セルジーン コーポレイション | 併用療法を用いて癌を治療する方法 |
US20150273033A1 (en) | 2013-11-05 | 2015-10-01 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | 3-(5-胺基-2-甲基-4-側氧基-4h-喹唑啉-3-基)-哌啶-2,6-二酮之調配物 |
JP2017521396A (ja) | 2014-07-11 | 2017-08-03 | セルジーン コーポレイション | 癌のための併用療法 |
EA201890585A1 (ru) | 2015-08-27 | 2018-11-30 | Селджин Корпорейшн | Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
CA3006758A1 (en) | 2015-12-02 | 2017-06-08 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
-
2016
- 2016-07-01 EP EP16739642.3A patent/EP3316888A1/en not_active Withdrawn
- 2016-07-01 AU AU2016288246A patent/AU2016288246A1/en not_active Abandoned
- 2016-07-01 EA EA201890199A patent/EA201890199A1/ru unknown
- 2016-07-01 MX MX2018000216A patent/MX2018000216A/es unknown
- 2016-07-01 BR BR112017028530A patent/BR112017028530A2/pt not_active Application Discontinuation
- 2016-07-01 CA CA2991164A patent/CA2991164A1/en not_active Abandoned
- 2016-07-01 WO PCT/US2016/040718 patent/WO2017004532A1/en active Application Filing
- 2016-07-01 US US15/741,130 patent/US10973822B2/en active Active
- 2016-07-01 KR KR1020187002705A patent/KR20180023968A/ko unknown
- 2016-07-01 JP JP2017568243A patent/JP6727237B2/ja not_active Expired - Fee Related
-
2020
- 2020-06-30 JP JP2020112519A patent/JP2020172502A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2991164A1 (en) | 2017-01-05 |
JP2018524347A (ja) | 2018-08-30 |
AU2016288246A1 (en) | 2018-02-01 |
EA201890199A1 (ru) | 2018-06-29 |
US20180193342A1 (en) | 2018-07-12 |
EP3316888A1 (en) | 2018-05-09 |
KR20180023968A (ko) | 2018-03-07 |
US10973822B2 (en) | 2021-04-13 |
BR112017028530A2 (pt) | 2018-08-28 |
WO2017004532A1 (en) | 2017-01-05 |
JP2020172502A (ja) | 2020-10-22 |
JP6727237B2 (ja) | 2020-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018000216A (es) | Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos. | |
ZA202202559B (en) | Kras g12c inhibitors and methods of using the same | |
MX2020002502A (es) | Inhibidores de kras g12c y metodos para utilizarlos. | |
MY196830A (en) | Kras g12c inhibitors and methods of using the same | |
MX2021007790A (es) | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
MX2020012731A (es) | Inhibidores de kras g12c y metodos para su uso. | |
MX2018006745A (es) | Metodos de tratamiento de neoplasias malignas. | |
PH12017501999A1 (en) | K-ras modulators | |
MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
PL3293201T3 (pl) | Łączenie adenowirusa i inhibitorów punktów kontrolnych do leczenia nowotworu | |
MX2017009246A (es) | Farmaco de combinacion. | |
MX2018003301A (es) | Inhibidores de pcna. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
NZ779760A (en) | Pcna inhibitors |